Journal Article DKFZ-2019-01484

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png
Lung cancer mortality reduction by LDCT screening - results from the randomised German LUSI trial.

 ;  ;  ;  ;  ;  ;  ;  ;  ;  ;

2020
Wiley-Liss Bognor Regis

International journal of cancer 146(6), 1503-1513 () [10.1002/ijc.32486]
 GO

This record in other databases:  

Please use a persistent id in citations: doi:

Abstract: In 2011, the US National Lung Cancer Screening Trial (NLST) reported a 20% reduction of lung cancer mortality after regular screening by low-dose computed tomography (LDCT), as compared to X-ray screening. The introduction of lung cancer screening programs in Europe awaits confirmation of these first findings from European trials that started in parallel with the NLST. The German Lung cancer Screening Intervention ('LUSI') is a randomized trial among 4,052 long-term smokers, 50-69 years of age, recruited from the general population, comparing 5 annual rounds of LDCT screening (screening arm; n=2,029 participants) with a control arm (n=2,023) followed by annual postal questionnaire inquiries. Data on lung cancer incidence and mortality and vital status were collected from hospitals or office-based physicians, cancer registries, population registers and health offices. Over an average observation time of 8.8 years after randomization, the hazard ratio for lung cancer mortality was 0.74 [95%CI: 0.46 - 1.19; p=0.21] among men and women combined. Modelling by sex, however showed a statistically significant reduction in lung cancer mortality among women (HR=0.31 [95%CI: 0.10 - 0.96], p=0.04), but not among men (HR=0.94 [95%CI: 0.54 - 1.61], p=0.81) screened by LDCT (pheterogeneity = 0.09). Findings from LUSI are in line with those from other trials, including NLST, that suggest a stronger reduction of lung cancer mortality after LDCT screening among women as compared to men. This heterogeneity could be the result of different relative counts of lung tumor sub-types occurring in men and women. This article is protected by copyright. All rights reserved.

Classification:

Note: 2020 Mar 15;146(6):1503-1513 #EA:C020#LA:E010#

Contributing Institute(s):
  1. C020 Epidemiologie von Krebs (C020)
  2. E010 Radiologie (E010)
Research Program(s):
  1. 315 - Imaging and radiooncology (POF3-315) (POF3-315)

Appears in the scientific report 2020
Database coverage:
Medline ; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; NationallizenzNationallizenz ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection
Click to display QR Code for this record

The record appears in these collections:
Document types > Articles > Journal Article
Institute Collections > E010
Institute Collections > C020
Public records
Publications database

 Record created 2019-06-12, last modified 2024-02-29



Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)